OAB-040: BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial

Palacios, Juan José Lahuerta; Ubieto, Ana Jiménez; Rosiñol, Laura; López, Joaquín Martinez; Cedena, María Teresa; Puig, Noemí; Oriol, Albert; Blanchard, María Jesús; Bargay, Joan; Martín, Jesús; martinez, Rafael; Sureda, Anna; Rubia, Javier de la; Hernández, Miguel teodoro; Cabañas, Valentín; krsnik, Isabel; Palomera, Luis; Casado, Felipe; Gonzalez-Montes, Yolanda; Fuente, Felipe de Arriba de la; Mateos, María‐Victoria; Miguel, Jesús F. San; Bladé, Joan

doi:10.1016/s2152-2650(22)00313-5

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At a median follow-up of 84.4 months, the median PFS was 80.8 months. 50 An induction analysis of the pooled population showed that the rate of ≥VGPR was 66.6% and increased with more cycles during RVd induction, ranging from 55.6% to 70.4% for cycles 3-5 and post-induction, respectively. The rate of MRD negativity after induction was 28.8%.…”

Section: Rvd: Phase III Studies In Newly Diagnosed Multiple Myelomamentioning

confidence: 96%

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Richardson,

Durie,

Rosiñol

et al. 2023

haematol

Self Cite

View full text Add to dashboard Cite

To improve patient outcomes in the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patient prognosis becomes worse after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) receive optimal frontline therapy. The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has consistently demonstrated a tolerable safety profile with significant and clinically relevant benefit, including deep and durable responses with improved survival in patients with NDMM regardless of their transplant eligibility. Furthermore, comparative studies evaluating this triplet against both doublets and other triplet regimens have established RVd as a standard of care in this setting based upon its remarkable and concordant efficacy. Given the breadth of clinical data, physician familiarity, inclusion in treatment guidelines, and the emerging potential of RVd-containing quadruplet regimens, RVd will likely continue as a key cornerstone of NDMM therapy, and its role will therefore likely continue to grow as a therapeutic backbone in the initial treatment of MM.

show abstract

Section: Rvd: Phase III Studies In Newly Diagnosed Multiple Myelomamentioning

confidence: 96%

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Richardson,

Durie,

Rosiñol

et al. 2023

haematol

Self Cite

View full text Add to dashboard Cite

show abstract

“…In patients who are newly diagnosed and transplant-eligible (NDTE), median PFS is surpassing 5 years with 3-drug combinations. 1 , 2 , 3 , 4 With quadruplets, PFS rates at 3 years are >80%. 5 , 6 Unprecedented PFS has also been observed in newly diagnosed patients who are transplant-ineligible (NDTI) 7 , 8 , 9 and with relapsed/refractory MM (RRMM).…”

mentioning

confidence: 99%

Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma

Paiva,

Zherniakova,

Nuñez-Córdoba

et al. 2023

Blood Advances

Self Cite

View full text Add to dashboard Cite

OAB-040: BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial

Cited by 2 publications

References 0 publications

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma

Contact Info

Product

Resources

About